TECH - Bio-Techne Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Minneapolis,
United States
Type: Equity
TECH price evolution
TECH
| (in millions $) | 31 Jan 2025 | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $151.79 | $139.91 | ||
| Short term investments | $1.07 | $5.4 | ||
| Net receivables | $223.69 | $241.39 | $227.89 | |
| Inventory | $185.04 | $179.73 | $179.5 | |
| Total current assets | $648.57 | $617.42 | $610.65 | |
| Long term investments | ||||
| Property, plant & equipment | $343.16 | $342.44 | $340.99 | |
| Goodwill & intangible assets | $1479.74 | $1497.39 | ||
| Total noncurrent assets | $2086.45 | $2110.52 | ||
| Total investments | $1.07 | $5.4 | ||
| Total assets | $2736.02 | $2703.87 | $2721.17 | |
| Current liabilities | ||||
| Accounts payable | $31.56 | $37.97 | $28.89 | |
| Deferred revenue | $27.93 | $30.11 | ||
| Short long term debt | $12.92 | $12.98 | ||
| Total current liabilities | $142.13 | $159.38 | $149.82 | |
| Long term debt | $300 | $406.62 | $481.75 | |
| Total noncurrent liabilities | $475.64 | $556.98 | ||
| Total debt | $419.54 | $494.73 | ||
| Total liabilities | $597.37 | $635.02 | $706.79 | |
| Shareholders' equity | ||||
| Retained earnings | $1341.17 | $1325.25 | $1297.69 | |
| Other shareholder equity | -$60.09 | -$78.32 | -$75.31 | |
| Total shareholder equity | $2068.85 | $2014.38 | ||
| (in millions $) | 31 Jan 2025 | 31 Jan 2024 | 31 Jan 2023 | 30 Jul 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $151.79 | $180.57 | $172.57 | $199.09 |
| Short term investments | $1.07 | $23.74 | $74.46 | $32.46 |
| Net receivables | $241.39 | $218.47 | $194.55 | $145.38 |
| Inventory | $179.73 | $171.64 | $141.12 | $116.75 |
| Total current assets | $617.42 | $621.48 | $605.56 | $510.61 |
| Long term investments | ||||
| Property, plant & equipment | $342.44 | $324.53 | $288.8 | $207.91 |
| Goodwill & intangible assets | $1479.74 | $1407.38 | $1353.62 | $1459.04 |
| Total noncurrent assets | $2086.45 | $2017.21 | $1689.25 | $1752.35 |
| Total investments | $1.07 | $23.74 | $74.46 | $32.46 |
| Total assets | $2703.87 | $2638.69 | $2294.8 | $2262.96 |
| Current liabilities | ||||
| Accounts payable | $37.97 | $29.18 | $33.87 | $99.96 |
| Deferred revenue | $27.93 | $23.07 | $23.41 | $19 |
| Short long term debt | $12.92 | $11.2 | $24.43 | $24.1 |
| Total current liabilities | $159.38 | $128.51 | $176.02 | $152.28 |
| Long term debt | $406.62 | $443.77 | $301.54 | $328.83 |
| Total noncurrent liabilities | $475.64 | $543.67 | $417.78 | $539.44 |
| Total debt | $419.54 | $454.96 | $325.97 | $420.55 |
| Total liabilities | $635.02 | $672.18 | $593.79 | $691.72 |
| Shareholders' equity | ||||
| Retained earnings | $1325.25 | $1309.46 | $1122.92 | $1085.46 |
| Other shareholder equity | -$78.32 | -$66.06 | -$75.2 | $1571.23 |
| Total shareholder equity | $2068.85 | $1966.52 | $1701.77 | $1562.97 |
| (in millions $) | 1 May 2025 | 31 Jan 2025 | 30 Oct 2024 | 30 Jul 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $289.46 | |||
| Cost of revenue | ||||
| Gross Profit | $187.91 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $135.23 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $6.57 | |||
| Interest expense | -$0.88 | |||
| Net income | ||||
| Net income | $33.59 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Dec 2024 | 31 Jan 2024 | 31 Jan 2023 | 30 Jul 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1159.06 | $931.03 | ||
| Cost of revenue | $389.33 | $298.18 | ||
| Gross Profit | $769.73 | $632.85 | ||
| Operating activities | ||||
| Research & development | $96.66 | $70.6 | ||
| Selling, general & administrative | $466.38 | $324.95 | ||
| Total operating expenses | $563.04 | $395.74 | ||
| Operating income | $206.69 | $237.3 | ||
| Income from continuing operations | ||||
| EBIT | $201.43 | $162.95 | ||
| Income tax expense | $17.58 | $8.59 | ||
| Interest expense | $15.74 | $13.95 | ||
| Net income | ||||
| Net income | $168.1 | $140.41 | ||
| Income (for common shares) | $168.1 | $140.41 | ||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $40.59 | $49.06 | $27.46 | |
| Operating activities | ||||
| Depreciation | $28.06 | $27.31 | $27.8 | |
| Business acquisitions & disposals | $4.85 | -$3.28 | ||
| Stock-based compensation | $7.06 | $8.13 | $12.75 | |
| Total cash flows from operations | $75.5 | $80.99 | $83.12 | |
| Investing activities | ||||
| Capital expenditures | -$17.98 | -$16.44 | -$14.86 | |
| Investments | $4.32 | -$5.53 | ||
| Total cash flows from investing | -$21.68 | -$8.81 | -$16.44 | -$23.67 |
| Financing activities | ||||
| Dividends paid | -$12.69 | -$12.63 | -$12.58 | -$12.56 |
| Sale and purchase of stock | $22.93 | $18.33 | -$74.77 | |
| Net borrowings | -$70 | -$58 | $7 | |
| Total cash flows from financing | -$11.57 | -$60.09 | -$52.42 | -$81.4 |
| Effect of exchange rate | $5.12 | $5.28 | -$2.35 | $3.42 |
| Change in cash and equivalents | $35.75 | $11.88 | $9.78 | -$18.53 |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 30 Jul 2021 |
|---|---|---|---|---|
| Net income | $168.1 | $285.26 | $272.05 | $140.41 |
| Operating activities | ||||
| Depreciation | $111.71 | $107.24 | $101.07 | $87.75 |
| Business acquisitions & disposals | -$162.71 | -$242.14 | -$225.91 | |
| Stock-based compensation | $38.04 | $39.23 | $42.18 | $48.98 |
| Total cash flows from operations | $298.98 | $254.39 | $325.27 | $352.16 |
| Investing activities | ||||
| Capital expenditures | -$62.88 | -$38.24 | -$44.91 | -$44.3 |
| Investments | $22.56 | $14.74 | -$51.94 | $26.69 |
| Total cash flows from investing | -$203.03 | -$265.65 | -$96.85 | -$243.52 |
| Financing activities | ||||
| Dividends paid | -$50.42 | -$50.28 | -$50.19 | -$49.62 |
| Sale and purchase of stock | -$19.11 | $10.25 | -$83.8 | $21.91 |
| Net borrowings | -$31 | $94 | -$85.5 | -$15.5 |
| Total cash flows from financing | -$122.4 | $22.62 | -$242.85 | -$62.55 |
| Effect of exchange rate | -$2.33 | -$3.36 | -$12.09 | $6.37 |
| Change in cash and equivalents | -$28.78 | $8 | -$26.52 | $52.47 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.31 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |